Jean G MacFadyen Selected Research

canakinumab

12/2021	Canakinumab's Effect Against Subsequent Gout Flares and High-Sensitivity C-Reactive Protein Levels: A Causal Mediation Analysis.
10/2020	Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
1/2020	Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
1/2020	Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
1/2019	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
10/2018	Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
10/2018	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
1/2018	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
1/2018	Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
10/2017	Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean G MacFadyen Research Topics

Disease

14	Myocardial Infarction 10/2020 - 11/2008
10	Inflammation (Inflammations) 01/2021 - 01/2017
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 01/2004
7	Stroke (Strokes) 10/2020 - 11/2008
7	Unstable Angina 10/2018 - 11/2008
6	Thrombosis (Thrombus) 12/2021 - 10/2017
5	Atherosclerosis 01/2021 - 10/2017
5	Neoplasms (Cancer) 10/2017 - 11/2008
3	Infections 01/2020 - 01/2017
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 08/2012
2	Gout 12/2021 - 10/2018
2	Coronary Disease (Coronary Heart Disease) 01/2020 - 01/2019
2	Heart Failure 01/2020 - 06/2015
2	Myalgia 06/2013 - 04/2011
2	Muscular Diseases (Myopathy) 06/2013 - 11/2008
2	Venous Thromboembolism 08/2012 - 04/2009
2	Hyperlipidemias (Hyperlipidemia) 11/2009 - 11/2008
1	Anemia 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Neutropenia 01/2020
1	Skin Neoplasms (Skin Cancer) 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Chronic Renal Insufficiency 01/2018
1	Sepsis (Septicemia) 10/2017
1	Neoplasm Metastasis (Metastasis) 10/2017
1	Lung Neoplasms (Lung Cancer) 10/2017
1	Muscle Weakness 04/2011
1	Diabetes Mellitus 04/2011
1	Dyslipidemias (Dyslipidemia) 03/2010
1	Ischemic Stroke 01/2010
1	Venous Thrombosis (Deep-Vein Thrombosis) 04/2009
1	Pulmonary Embolism 04/2009
1	Wounds and Injuries (Trauma) 04/2009
1	Vascular Diseases (Vascular Disease) 02/2009

Drug/Important Bio-Agent (IBA)

18	C-Reactive ProteinIBA 12/2021 - 11/2008
11	canakinumab FDA Link 12/2021 - 01/2017
11	Rosuvastatin Calcium (Crestor)FDA Link 06/2013 - 11/2008
10	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2015 - 11/2008
7	LDL CholesterolIBA 01/2020 - 11/2008
6	Interleukin-6 (Interleukin 6)IBA 01/2020 - 10/2017
5	Monoclonal AntibodiesIBA 01/2019 - 01/2017
4	InterleukinsIBA 10/2020 - 10/2017
4	CholesterolIBA 01/2020 - 11/2008
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2020
3	InflammasomesIBA 01/2020 - 10/2017
2	CytokinesIBA 01/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 10/2017
2	omega-Chloroacetophenone (Mace)IBA 01/2020 - 10/2018
2	LipidsIBA 01/2018 - 01/2017
2	LDL Lipoproteins (beta Lipoproteins)IBA 07/2011 - 11/2008
1	methotrexate polyglutamateIBA 01/2021
1	Interleukin-18 (Interleukin 18)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	IronIBA 01/2020
1	EnzymesIBA 01/2019
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	Uric Acid (Urate)IBA 10/2018
1	NLR ProteinsIBA 10/2017
1	Proteins (Proteins, Gene)FDA Link 10/2017
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 03/2016
1	Vitamin D FDA LinkGeneric 03/2016
1	AnionsIBA 06/2013
1	Peptides (Polypeptides)IBA 06/2013
1	Glucose (Dextrose)FDA LinkGeneric 08/2012
1	A 17 (A-17)IBA 08/2012
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 05/2012
1	oxidized low density lipoproteinIBA 04/2011
1	HDL CholesterolIBA 07/2010
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 07/2010
1	VitaminsIBA 01/2004
1	AntioxidantsIBA 01/2004
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2004

Therapy/Procedure

10	Therapeutics 01/2020 - 02/2009
2	Aftercare (After-Treatment) 10/2018 - 05/2012
1	Secondary Prevention 01/2020